Replimune Group (NASDAQ:REPL) Trading Down 5.6% – Should You Sell?

Replimune Group, Inc. (NASDAQ:REPL) dropped 5.6% during mid-day trading on Friday . The company traded as low as $10.99 and last traded at $10.95. Approximately 384,744 shares were traded during mid-day trading, a decline of 45% from the average daily volume of 694,876 shares. The stock had previously closed at $11.60.

Wall Street Analyst Weigh In

REPL has been the subject of a number of analyst reports. JPMorgan Chase & Co. increased their price objective on shares of Replimune Group from $16.00 to $18.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 26th. Jefferies Financial Group increased their price objective on shares of Replimune Group from $16.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday, December 4th. BMO Capital Markets upped their target price on shares of Replimune Group from $18.00 to $27.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 22nd. Finally, HC Wainwright upped their target price on shares of Replimune Group from $21.00 to $22.00 and gave the stock a “buy” rating in a research report on Thursday, February 13th. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Replimune Group currently has an average rating of “Buy” and an average target price of $19.43.

Replimune Group Trading Down 6.7 %

The company has a debt-to-equity ratio of 0.14, a current ratio of 11.43 and a quick ratio of 11.43. The stock’s 50-day moving average is $12.66 and its two-hundred day moving average is $12.15. The stock has a market cap of $833.30 million, a P/E ratio of -3.52 and a beta of 1.30.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings data on Wednesday, February 12th. The company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.70) by ($0.09). Equities research analysts anticipate that Replimune Group, Inc. will post -2.97 EPS for the current year.

Hedge Funds Weigh In On Replimune Group

Institutional investors have recently bought and sold shares of the business. Charles Schwab Investment Management Inc. lifted its position in Replimune Group by 12.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 484,797 shares of the company’s stock valued at $5,313,000 after purchasing an additional 52,498 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Replimune Group by 17.9% in the third quarter. Geode Capital Management LLC now owns 1,428,301 shares of the company’s stock valued at $15,657,000 after acquiring an additional 217,308 shares during the period. Barclays PLC raised its stake in shares of Replimune Group by 165.5% in the third quarter. Barclays PLC now owns 158,491 shares of the company’s stock valued at $1,738,000 after acquiring an additional 98,791 shares during the period. State Street Corp raised its stake in shares of Replimune Group by 102.1% in the third quarter. State Street Corp now owns 2,340,042 shares of the company’s stock valued at $25,647,000 after acquiring an additional 1,182,181 shares during the period. Finally, Baker BROS. Advisors LP raised its stake in shares of Replimune Group by 10.0% in the third quarter. Baker BROS. Advisors LP now owns 11,045,336 shares of the company’s stock valued at $121,057,000 after acquiring an additional 1,000,000 shares during the period. Institutional investors own 92.53% of the company’s stock.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.